Latest Medtech News

Cambium Bio has secured a strategic partnership with French pharmaceutical leader Benta SAS to commercialise its regenerative dry eye treatment, Elate Ocular, across Europe and the Middle East. This follows a second platelet-lysate licensing deal within days, underscoring growing industry confidence in Cambium’s platform.

Cambium Bio has struck a licensing deal with Keke Medtech to commercialise its fibrin biologic in dental applications, unlocking new markets and non-dilutive funding.

Osteopore Limited has established OsteoRx, a new special purpose vehicle, with an initial AUD 0.5 million investment to accelerate breakthroughs in cellular regenerative medicine. This strategic move integrates a controlling stake in US-based RxCell Inc, expanding Osteopore’s footprint in the fast-growing stem cell market.

Rewardle Holdings reports a sharp 497% increase in half-year losses amid strategic investments in its MedTech partner CloudHolter and fintech expansions. Despite financial headwinds, the company advances its B2B2C platform with a focus on growth and innovation.

Hydrix Limited narrowed its FY2025 loss to $2.92 million, driven by significant cost reductions and steady revenue from expanding international medtech clients. Despite ongoing challenges in sales cycles and funding, the company remains focused on innovation and strategic investments.

4DMedical Limited reported a 56% jump in FY2025 operating revenue driven by SaaS growth, while narrowing its net loss to $30.1 million. The company also secured $13.9 million in capital and a $10 million funding facility to accelerate product commercialisation.

Scalare Partners reports a 26% rise in FY25 revenue, driven by strong service demand and key acquisitions, including Inhouse Ventures and the pending Tank Stream Labs deal.

Talius Group Limited reported a 21% increase in sales revenue for the first half of 2025, driven by strong hardware sales and recurring software subscriptions. The company also completed a major contract rollout and achieved significant cost reductions, positioning itself for growth amid evolving aged care sector dynamics.

Navigator Global Investments Limited (ASX, NGI) reported a robust 80% increase in net profit for FY25, driven by strong performance fees and strategic acquisitions including 1315 Capital Partners. The company also announced key board transitions as it reviews its dividend policy amid growth ambitions.

Rewardle Holdings Limited reported a 2.8% revenue increase to $9.68 million for FY24 but swung to a $3.44 million net loss, driven by rising expenses and associate losses. The company expanded its footprint with acquisitions in grocery delivery and fintech, while deepening its stake in AI-powered health tech partner CloudHolter.

Adherium Limited reports a robust 30% increase in US remote patient monitoring users and closes a $4.5 million capital raise, positioning itself for accelerated growth under new leadership.

Hydrix Limited reports steady June quarter revenues with a 10% rise from the prior quarter, supported by new contract wins and a robust $40 million project pipeline.